A Takeda spokesperson told Fierce Biotech that it was on track to open its new R&D facility being developed by BioMed Realty ...

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. | Madrigal Pharmaceuticals is continuing to ...

During the first year of the Trump administration, signs of an anti-mRNA slant within the FDA and the Department of Health ...

Following Moderna's public rebuke of the FDA's refusal to take up its application for a next-gen flu vaccine, the regulator has doubled down and accused Moderna of potentially putting patients at risk ...

GE HealthCare has launched a new technology designed to help hospitals keep up with the maintenance and repair demands of a growing number of connected medical devices. | GE HealthCare has launched a ...

A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma exacerbation ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...

In October of last year, Kailera Therapeutics unveiled a whopping $600 mill | Kailera Therapeutics and its China partner ...

Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...

Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies.  | The deal allows CSL to ...

ILiAD Biotechnologies has closed an oversubscribed $115 million series B fundraise to support the company’s next-generation ...